Press Release
We are pleased to announce that SAGA will be presenting at the Jefferies Global Healthcare Conference in London—celebrating the 16th anniversary of Europe’s largest healthcare-dedicated investor event.
📌 Presentation Details
Date: Wednesday, November 19, 2025
Time: 1:00–1:25 PM (GMT)
We look forward to engaging with leaders across the healthcare and investment communities. Our Executive Chairman, Roopom Banerjee, will highlight how Pathlight™, our structural-variant–based MRD assay, is changing expectations for recurrence detection and post-treatment surveillance in cancer care.
Viewers can access the live presentation and the 90-day on-demand replay here: https://wsw.com/webcast/jeff332/saga/1820852
Pathlight™ is a novel, personalized, tumor-informed multi-cancer molecular residual disease (MRD) platform developed by SAGA Diagnostics. It delivers industry-leading sensitivity and specificity for detecting cancer recurrence and monitoring treatment response by analyzing circulating tumor DNA (ctDNA).
Pathlight uses a proprietary combination of whole genome sequencing and digital PCR to identify and track large-scale genomic changes known as structural variants (SVs) – stable, truncal biomarkers that provide a clearer, earlier indication of disease recurrence. By optimizing for SVs, Pathlight enables ultra-sensitive detection of recurrence and precise monitoring of treatment response in early-stage and metastatic disease.
This advanced approach empowers oncologists to make timely, confident decisions—helping patients avoid unnecessary treatments or receive interventions sooner when needed. Pathlight supports accurate, longitudinal assessments of disease status, enhancing care across the entire patient journey.
Pathlight is covered by Medicare for early-stage breast cancer across all subtypes and is actively used in clinical studies by leading clinical institutions, national cancer centers and major pharmaceutical companies. For more information, visit www.pathlightMRD.com.
SAGA Diagnostics® is redefining the early detection of molecular residual disease (MRD), empowering treatment decisions with greater insight and confidence. Pathlight™, the company’s flagship product, is an ultra-sensitive, blood-based, multi-cancer MRD test that is now available for commercial use in the U.S and reimbursed for patients with early stage breast cancer. SAGA is partnering with pharmaceutical and biotechnology companies, as well as commercial entities, to support early through late-stage cancer development programs across a range of cancer types. SAGA’s headquarters and CLIA-certified laboratory are located in the heart of the life science ecosystem in Research Triangle Park, North Carolina. SAGA Diagnostics combines world-class genomic expertise with a leadership team deeply experienced in MRD, all aligned in the mission to intercept cancer at its earliest stages when it is most treatable. For more information, visit sagadiagnostics.com.
